Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from China’s NMPA for Melanoma Treatment

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment o...

April 02, 2025 | Wednesday | News
Castle Biosciences to Present Key Data on DecisionDx-Melanoma at EADO 2025 Congress

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, will share data via two poster presentations at the ...

April 02, 2025 | Wednesday | News
Inventiva Completes Patient Enrollment in Phase 3 NATiV3 Trial for MASH Treatment

Inventiva ("Inventiva" or the "Company"), a clinical-focused biopharmaceutical company focused on the development of orally administered small molecule dru...

April 02, 2025 | Wednesday | News
Hoth Therapeutics Receives USPTO Filing Receipt for New Patent on HT-001 Formulation

 Hoth Therapeutics, Inc. , a patient-focused clinical-stage biopharmaceutical company, announced that it has received an official Filing Rec...

April 01, 2025 | Tuesday | News
Merck Exercises Global Commercialization Option for Pimicotinib, Marking a Milestone in Partnership with Abbisko Therapeutics

Abbisko Therapeutics Co., Ltd. announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fe...

April 01, 2025 | Tuesday | News
Alnylam Presents New Data from HELIOS-B Trial at ACC.25, Highlighting Vutrisiran’s Impact on ATTR-CM Treatment

Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced moderated poster presentations of new data from the landmark HELIOS-B...

March 31, 2025 | Monday | News
Regeneron and Sanofi Receive Approval for Dupixent® in Japan to Treat Chronic Obstructive Pulmonary Disease (COPD)

TARRYTOWN -- Regeneron Pharmaceuticals, and Sanofi announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan ...

March 31, 2025 | Monday | News
CHMP Recommends Opdivo® for EU Approval as Neoadjuvant and Adjuvant Treatment for Resectable NSCLC

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a...

March 31, 2025 | Monday | News
AstraZeneca’s Calquence® Combination Therapy Recommended for EU Approval in Untreated Mantle Cell Lymphoma

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Un...

March 31, 2025 | Monday | News
Novartis Announces FDA Approval for Expanded Use of Pluvicto® in mCRPC, Tripling Eligible Patient Access

Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) for patients with pro...

March 31, 2025 | Monday | News
China Grants Breakthrough Therapy Designation to Innovent’s IBI363 for Hard-to-Treat Melanoma

Innovent Biologics, Inc.  a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the trea...

March 31, 2025 | Monday | News
FDA Approves CABOMETYX® for Treatment of Advanced Neuroendocrine Tumors in Adults and Pediatric Patients

 Exelixis, Inc.  announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the tre...

March 28, 2025 | Friday | News
Eli Lilly Expands LillyDirect Platform to Improve Access to Alzheimer's Disease Care in the U.S.

Eli Lilly and Company (LLY) has expanded its LillyDirect digital healthcare platform to offer connections to independent in-person and telehealth opti...

March 28, 2025 | Friday | News
Rani Therapeutics Announces Promising Preclinical Data for RT-114, an Oral GLP-1/GLP-2 Dual Agonist for Obesity Treatment

Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced pharmacokinetic a...

March 27, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close